Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH
14 search results for:

BTK inhibitors 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 06-05-2022 | Rheumatoid arthritis | News | Article

    Adding BTK inhibitor to upadacitinib offers no benefit in RA

    Treatment with a fixed-dose combination of the novel BTK inhibitor elsubrutinib and the JAK inhibitor upadacitinib offers no additional benefit over upadacitinib alone for people with rheumatoid arthritis, suggest phase 2 trial results.

    Author:
    Claire Barnard
    Published in:
    Lancet Rheumatol 2022; doi:10.1016/S2665-9913(22)00092-3
  2. 16-08-2021 | Temporal cell arteritis | Teaser

    New additions to the Adis Journal Club

    A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

  3. 08-02-2022 | Temporal cell arteritis | Teaser

    Rituximab and rheumatology practice in the COVID-19 era

    How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?

  4. 24-05-2021 | ACR 2021 | Teaser

    ACR Convergence 2021 highlights

    3–9 November: Keep up with the latest news and interviews from the conference.

  5. 06-09-2021 | Pneumonia | Teaser

    Anifrolumab for the treatment of lupus

    Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

  6. 26-10-2020 | Vitamin D | Teaser

    Get ready for ACR Convergence 2020

    5 – 9 November: Preview the conference with session recommendations and updates on upcoming coverage.

  7. 10-05-2021 | Temporal cell arteritis | Teaser

    Febuxostat and cardiovascular risk in people with gout

    How will the FAST trial results impact regulatory guidance & clinical practice?

  8. 18-11-2020 | Temporal cell arteritis | Teaser

    Telemedicine in rheumatology

    Experts discuss the increasing use of telemedicine in rheumatology during the COVID-19 pandemic.

  9. 11-11-2020 | ACR 2020 | Conference coverage | Article

    Evobrutinib fails to improve response rate in refractory RA patients

    “Whilst targeting BTK seems safe and well tolerated, this did not appear to be a significantly effective approach in improving the signs and symptoms of patients with rheumatoid arthritis,” Buch commented.

    Author:
    Lucy Piper
    Published in:
    ACR Convergence virtual meeting; 5–9 November 2020
  10. 18-11-2019 | Systemic lupus erythematosus | ACR/ARP 2019 | Article

    No benefit of add-on fenebrutinib for patients with SLE

    However, despite this lack of efficacy, fenebrutinib resulted in “maximal inhibition of a BTK-dependent pathway biomarker at [week] 48,” reported Isenberg.

    Published in:
    Arthritis Rheumatol 2019; 71 (suppl 10) ACR/ARP 2019; Atlanta, Georgia, USA: 8–13 November
  11. 13-06-2019 | Rheumatoid arthritis | News | Article

    Positive results for fenebrutinib in patients with biologic DMARD refractory RA

    Fenebrutinib has shown efficacy for reducing rheumatoid arthritis activity in patients with an inadequate response to either methotrexate or tumor necrosis factor inhibitors, phase II study findings show.

    Published in:
    Ann Rheum Dis 2019; 78 : 80─81 (abstract) European Congress of Rheumatology 2019; Madrid, Spain: 12–15 June
  12. 14-06-2019 | Rheumatoid arthritis | EULAR 2019 | Article

    Expert commentary: Fenebrutinib in RA

    Roy Fleischmann gives his thoughts on the phase IIb fenebrutinib findings in patients with biologic DMARD-refractory rheumatoid arthritis (1:09).

    Published in:
    European Congress of Rheumatology 2019; Madrid, Spain: 12–15 June
  13. 13-06-2019 | Fenebrutinib | EULAR 2019 | Teaser
    EULAR 2019

    Fenebrutinib in refractory RA

    News story |  Positive results for fenebrutinib in patients with biologic DMARD refractory RA Researcher comment | WATCH: The lead investigator discusses the findings Expert commentary : WATCH: Rheumatologist Roy Fleischmann's view of the findings

  14. 12-06-2019 | Rheumatoid arthritis | EULAR 2019 | Article

    Researcher comment: Phase IIb study of fenebrutinib in RA patients

    Stanley Cohen discusses the key results for the multi-dose trial of fenebrutinib versus placebo and adalimumab in patients with rheumatoid arthritis refractory to methotrexate or prior tumor necrosis inhibitor therapy (2:05).

    Published in:
    European Congress of Rheumatology 2019; Madrid, Spain: 12–15 June
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.